AIRSUPRA represents a significant innovation in asthma treatment by combining albuterol, a fast-acting bronchodilator, with budesonide, an anti-inflammatory corticosteroid, in a single rescue inhaler. Unlike traditional rescue therapies that only address bronchoconstriction, AIRSUPRA targets both the immediate symptoms and the underlying inflammation that can lead to severe exacerbations. This dual-action approach is supported by robust clinical evidence from the BATURA Phase IIIb trial, which demonstrated statistically significant and clinically meaningful improvements across all primary and secondary endpoints compared to albuterol alone.

In practical use, AIRSUPRA offers patients an effective as-needed rescue treatment that not only relieves acute asthma symptoms but also reduces the risk of severe exacerbations and the need for systemic corticosteroids. The wearable, easy-to-use inhaler fits seamlessly into patients’ daily lives, providing immediate relief while addressing airway inflammation early. This makes AIRSUPRA especially valuable for patients with mild asthma, a group often underestimated in terms of risk but responsible for a significant proportion of severe attacks and asthma-related hospitalizations.